Neoplastic stem cells: Current concepts and clinical perspectives

Critical Reviews in Oncology/Hematology

Volumn 76, Issue 2, 2010, Pages 79-98

  Schulenburg, Axel ^a,b   Brämswig, Kira ^a   Herrmann, Harald ^a,b   Karlic, Heidrun ^b   Mirkina, Irina ^a,b   Hubmann, Rainer ^a,b   Laffer, Sylvia ^b   Marian, Brigitte ^c   Shehatr, Clemens ^a,b   Pehamba, Medhat ^b,d   Krepleerger, Hubert ^b,d   Grunt, Thomas ^a,b   Jäger, Ulrich ^a,b   Zielinski, Christoph C ^a,b   Valent, Peter ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d Universitatsklinik fur Dermatologie   (Austria)

Author keywords

Cancer stem cells; Drug resistance; Targeted therapy

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; CD133 ANTIGEN; GEMTUZUMAB OZOGAMICIN; HERMES ANTIGEN; HYBRID PROTEIN; IMATINIB; INTERLEUKIN 3 DIPHTHERIA TOXIN FUSION PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE MARROW CANCER; BRAIN CANCER; BREAST CANCER; CANCER INHIBITION; CANCER STEM CELL; CANCER SURVIVAL; CELL CLONE; CELL FUNCTION; CELL MATURATION; CELL POPULATION; CELL RENEWAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLON CANCER; DRUG DESIGN; DRUG EFFICACY; DRUG TARGETING; HEAD AND NECK CARCINOMA; HUMAN; LEUKEMIA CELL; LIVER CANCER; MELANOMA; MELANOMA CELL; MULTIPLE MYELOMA; MYELOID LEUKEMIA; NONHUMAN; PANCREAS CANCER; PHENOTYPIC PLASTICITY; PROSTATE CANCER; REVIEW; SARCOMA; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TUMOR MICROENVIRONMENT;

ANIMALS; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 77957797200     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.01.001     Document Type: Review

References (226)

1. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
2. Ailles L.E., Weissman I.L. Cancer stem cells in solid tumors. Curr Opin Biotechnol 2007, 18:460-466.
3. Cho R.W., Clarke M.F. Recent advances in cancer stem cells. Curr Opin Genet Dev 2008, 18:48-53.
4. Dalerba P., Cho R.W., Clarke M.F. Cancer stem cells: models and concepts. Annu Rev Med 2007, 58:267-284.
5. Korkaya H., Wicha M.S. Selective targeting of cancer stem cells: a new concept in cancer therapeutics. BioDrugs 2007, 21:299-310.
6. Besancon R., Valsesia-Wittmann S., Puisieux A., de Fromentel C.C., Maguer-Satta V. Cancer stem cells: the emerging challenge of drug targeting. Curr Med Chem 2009, 16:394-416.
7. Polyak K., Hahn W.C. Roots and stems: stem cells in cancer. Nat Med 2006, 12:296-300.
8. Lapidot T., Sirard C., Vormoor J., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648.
9. Bonnet D., Bhatia M., Wang J.C., Kapp U., Dick J.E. Cytokine treatment or accessory cells are required to initiate engraftment of purified primitive human hematopoietic cells transplanted at limiting doses into NOD/SCID mice. Bone Marrow Transplant 1999, 23:203-209.
10. Pearson T, Greiner DL, Shultz LD. Creation of "humanized" mice to study human immunity. Curr Protoc Immunol 2008 [Chapter 15:Unit 15 21].
11. Ishikawa F., Saito Y., Yoshida S., Harada M., Shultz L.D. The differentiative and regenerative properties of human hematopoietic stem/progenitor cells in NOD-SCID/IL2rgamma(null) mice. Curr Top Microbiol Immunol 2008, 324:87-94.
12. Hermann P.C., Huber S.L., Herrler T., et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 1:313-323.
13. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003, 100:3983-3988.
14. Bao S., Wu Q., McLendon R.E., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
15. Singh S.K., Hawkins C., Clarke I.D., et al. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
16. Li C., Heidt D.G., Dalerba P., et al. Identification of pancreatic cancer stem cells. Cancer Res 2007, 67:1030-1037.
17. Yang Z.F., Ho D.W., Ng M.N., et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 2008, 13:153-166.
18. Bhatia M., Wang J.C., Kapp U., Bonnet D., Dick J.E. Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. Proc Natl Acad Sci USA 1997, 94:5320-5325.
19. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3:730-737.
20. Al-Hajj M. Cancer stem cells and oncology therapeutics. Curr Opin Oncol 2007, 19:61-64.
21. Till J.E., Mc C.E. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res 1961, 14:213-222.
22. Taussig D.C., Miraki-Moud F., Anjos-Afonso F., et al. Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood 2008, 112:568-575.
23. Quintana E., Shackleton M., Sabel M.S., Fullen D.R., Johnson T.M., Morrison S.J. Efficient tumour formation by single human melanoma cells. Nature 2008, 456:593-598.
24. Fang D., Nguyen T.K., Leishear K., et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005, 65:9328-9337.
25. Dontu G., Abdallah W.M., Foley J.M., et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003, 17:1253-1270.
26. Ricci-Vitiani L., Lombardi D.G., Pilozzi E., et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445:111-115.
27. Hemmati H.D., Nakano I., Lazareff J.A., et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA 2003, 100:15178-15183.
28. Vermeulen L., Todaro M., de Sousa Mello F., et al. Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci USA 2008, 105:13427-13432.
29. Dexter T.M., Allen T.D., Lajtha L.G. Conditions controlling the proliferation of haemopoietic stem cells in vitro. J Cell Physiol 1977, 91:335-344.
30. Mayani H., Flores-Figueroa E., Chávez-González A. In vitro biology of human myeloid leukemia. Leuk Res 2009, 33:624-637.
31. Coulombel L., Eaves C., Kalousek D., Gupta C., Eaves A. Long-term marrow culture of cells from patients with acute myelogenous leukemia. Selection in favor of normal phenotypes in some but not all cases. J Clin Invest 1985, 75:961-969.
32. Lagneaux L., Delforge A., De Bruyn C., Bernier M., Bron D. Adhesion to bone marrow stroma inhibits apoptosis of chronic lymphocytic leukemia cells. Leuk Lymphoma 1999, 35:445-453.
33. Panayiotidis P., Jones D., Ganeshaguru K., Foroni L., Hoffbrand A.V. Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br J Haematol 1996, 92:97-103.
34. Reynolds B.A., Weiss S. Clonal and population analyses demonstrate that an EGF-responsive mammalian embryonic CNS precursor is a stem cell. Dev Biol 1996, 175:1-13.
35. Scadden D.T. The stem-cell niche as an entity of action. Nature 2006, 441:1075-1079.
36. Torok-Storb B. Cellular interactions. Blood 1988, 72:373-385.
37. Greenberger J.S. The hematopoietic microenvironment. Crit Rev Oncol Hematol 1991, 11:65-84.
38. Mayani H., Guilbert L.J., Janowska-Wieczorek A. Biology of the hemopoietic microenvironment. Eur J Haematol 1992, 49:225-233.
39. Rosel M., Khaldoyanidi S., Zawadzki V., Zoller M. Involvement of CD44 variant isoform v10 in progenitor cell adhesion and maturation. Exp Hematol 1999, 27:698-711.
40. Alakel N., Jing D., Muller K., Bornhauser M., Ehninger G., Ordemann R. Direct contact with mesenchymal stromal cells affects migratory behavior and gene expression profile of CD133+ hematopoietic stem cells during ex vivo expansion. Exp Hematol 2009, 37:504-513.
41. Raveh S., Gavert N., Spiegel I., Ben-Ze'ev A. The cell adhesion nectin-like molecules (Necl) 1 and 4 suppress the growth and tumorigenic ability of colon cancer cells. J Cell Biochem 2009, 108:326-336.
42. Gavert N., Ben-Shmuel A., Raveh S., Ben-Ze'ev A. L1-CAM in cancerous tissues. Expert Opin Biol Ther 2008, 8:1749-1757.
43. Bao S., Wu Q., Li Z., et al. Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res 2008, 68:6043-6048.
44. O'Brien C.A., Pollett A., Gallinger S., Dick J.E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445:106-110.
45. Dalerba P., Dylla S.J., Park I.K., et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 2007, 104:10158-10163.
46. Corbeil D., Fargeas C.A., Huttner W.B. Rat prominin, like its mouse and human orthologues, is a pentaspan membrane glycoprotein. Biochem Biophys Res Commun 2001, 285:939-944.
47. Corbeil D., Roper K., Hellwig A., et al. The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J Biol Chem 2000, 275:5512-5520.
48. Shmelkov S.V., St Clair R., Lyden D., Rafii S. AC133/CD133/Prominin-1. Int J Biochem Cell Biol 2005, 37:715-719.
49. Gunthert U. CD44: a multitude of isoforms with diverse functions. Curr Top Microbiol Immunol 1993, 184:47-63.
50. Sackstein R., Merzaban J.S., Cain D.W., et al. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat Med 2008, 14:181-187.
51. Hurt E.M., Kawasaki B.T., Klarmann G.J., Thomas S.B., Farrar W.L. CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer 2008, 98:756-765.
52. Schulenburg A., Cech P., Herbacek I., et al. CD44-positive colorectal adenoma cells express the potential stem cell markers musashi antigen (msi1) and ephrin B2 receptor (EphB2). J Pathol 2007, 213:152-160.
53. Botchkina I.L., Rowehl R.A., Rivadeneira D.E., et al. Phenotypic subpopulations of metastatic colon cancer stem cells: genomic analysis. Cancer Genomics Proteomics 2009, 6:19-29.
54. Schatton T., Murphy G.F., Frank N.Y., et al. Identification of cells initiating human melanomas. Nature 2008, 451:345-349.
55. White D.L., Saunders V.A., Dang P., et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006, 108:697-704.
56. Wu C., Alman B.A. Side population cells in human cancers. Cancer Lett 2008, 268:1-9.
57. Chen Y.C., Chen Y.W., Hsu H.S., et al. Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochem Biophys Res Commun 2009, 385:307-313.
58. Jiang F., Qiu Q., Khanna A., et al. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res 2009, 7:330-338.
59. Ucar D., Cogle C.R., Zucali J.R., et al. Aldehyde dehydrogenase activity as a functional marker for lung cancer. Chem Biol Interact 2009, 178:48-55.
60. Croker A.K., Goodale D., Chu J., et al. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med 2008, 13:2236-2252.
61. Cheung A.M., Wan T.S., Leung J.C., et al. Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential. Leukemia 2007, 21:1423-1430.
62. Ma S., Chan K.W., Lee T.K., et al. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Mol Cancer Res 2008, 6:1146-1153.
63. Douville J., Beaulieu R., Balicki D. ALDH1 as a functional marker of cancer stem and progenitor cells. Stem Cells Dev 2009, 18:17-26.
64. Florian S., Sonneck K., Hauswirth A.W., et al. Detection of molecular targets on the surface of CD34+/CD38- stem cells in various myeloid malignancies. Leuk Lymphoma 2006, 47:207-222.
65. Herrmann H Phenotypic and functional characterization of CD34+/CD38-/CD123+ leukemic progenitor (stem) cells in AML: a flow cytometric approach. Blood (ASH Annual Meeting Abstracts) 2008, 483.
66. Morimoto K., Kim S.J., Tanei T., et al. Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Sci 2009, 100:1062-1068.
67. Korkaya H., Paulson A., Iovino F., Wicha M.S. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 2008, 27:6120-6130.
68. Hewish M., Chau I., Cunningham D. Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine. Recent Patents Anticancer Drug Discov 2009, 4:54-72.
69. Gotoh N. Control of stemness by fibroblast growth factor signaling in stem cells and cancer stem cells. Curr Stem Cell Res Ther 2009, 4:9-15.
70. Phillips T.M., Kim K., Vlashi E., McBride W.H., Pajonk F. Effects of recombinant erythropoietin on breast cancer-initiating cells. Neoplasia 2007, 9:1122-1129.
71. Ponta H., Sherman L., Herrlich P.A. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003, 4:33-45.
72. Benedetti F. CD34+ cells: biological aspects. Tumori 1996, 82:S3-13.
73. Holyoake T.L., Jiang X., Jorgensen H.G., et al. Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3. Blood 2001, 97:720-728.
74. Kim J.B., Ko E., Han W., et al. CD24 cross-linking induces apoptosis in, and inhibits migration of, MCF-7 breast cancer cells. BMC Cancer 2008, 8:118.
75. Yu F., Yao H., Zhu P., et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007, 131:1109-1123.
76. Ginestier C., Hur M.H., Charafe-Jauffret E., et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1:555-567.
77. Vercauteren S.M., Sutherland H.J. CD133 (AC133) expression on AML cells and progenitors. Cytotherapy 2001, 3:449-459.
78. Fialkow P.J., Jacobson R.J., Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med 1977, 63:125-130.
79. Dick J.E. Complexity of the human acute myeloid leukemia stem cell compartment: implications for therapy. Biol Blood Marrow Transplant 2005, 11:9-11.
80. Majeti R., Becker M.W., Tian Q., et al. Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. Proc Natl Acad Sci USA 2009, 106:3396-3401.
81. Sievers E.L., Appelbaum F.R., Spielberger R.T., et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 1999, 93:3678-3684.
82. Sievers E.L., Larson R.A., Stadtmauer E.A., et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001, 19:3244-3254.
83. Feldman E., Kalaycio M., Weiner G., et al. Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195. Leukemia 2003, 17:314-318.
84. Jin L., Hope K.J., Zhai Q., Smadja-Joffe F., Dick J.E. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 2006, 12:1167-1174.
85. Hosen N., Park C.Y., Tatsumi N., et al. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc Natl Acad Sci USA 2007, 104:11008-11013.
86. van Rhenen A., van Dongen G.A., Kelder A., et al. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood 2007, 110:2659-2666.
87. Falini B., Nicoletti I., Martelli M.F., Mecucci C. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood 2007, 109:874-885.
88. Pearce D.J., Taussig D., Zibara K., et al. AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood 2006, 107:1166-1173.
89. Eisterer W., Jiang X., Christ O., et al. Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease. Leukemia 2005, 19:435-441.
90. Dorsey J.F., Cunnick J.M., Lanehart R., et al. Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors. Leukemia 2002, 16:1589-1595.
91. Jordanides N.E., Jorgensen H.G., Holyoake T.L., Mountford J.C. Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood 2006, 108:1370-1373.
92. Jiang X., Zhao Y., Smith C., et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 2007, 21:926-935.
93. Chen Y., Hu Y., Zhang H., Peng C., Li S. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat Genet 2009, 41:783-792.
94. Jamieson C.H. Chronic myeloid leukemia stem cells. Hematol Am Soc Hematol Educ Program 2008, 2008:436-442.
95. Zhao C., Chen A., Jamieson C.H., et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 2009, 458:776-779.
96. Yee K.W., Zeng Z., Konopleva M., et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2006, 12:5165-5173.
97. Guzman M.L., Neering S.J., Upchurch D., et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001, 98:2301-2307.
98. Recher C., Beyne-Rauzy O., Demur C., et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 2005, 105:2527-2534.
99. Druker B.J., Tamura S., Buchdunger E., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996, 2:561-566.
100. Chen Z.X., Xue Y.Q., Zhang R., et al. A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood 1991, 78:1413-1419.
101. Moliterno A.R., Williams D.M., Rogers O., Isaacs M.A., Spivak J.L. Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens. Exp Hematol 2008, 36:1480-1486.
102. Catani L., Zini R., Sollazzo D., et al. Molecular profile of CD34+ stem/progenitor cells according to JAK2V617F mutation status in essential thrombocythemia. Leukemia 2009, 23:997-1000.
103. Li S., Kralovics R., De Libero G., Theocharides A., Gisslinger H., Skoda R.C. Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations. Blood 2008, 111:3863-3866.
104. Lataillade J.J., Pierre-Louis O., Hasselbalch H.C., et al. Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence. Blood 2008, 112:3026-3035.
105. Cobaleda C., Gutierrez-Cianca N., Perez-Losada J., et al. A primitive hematopoietic cell is the target for the leukemic transformation in human philadelphia-positive acute lymphoblastic leukemia. Blood 2000, 95:1007-1013.
106. Hong D., Gupta R., Ancliff P., et al. Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science 2008, 319:336-339.
107. Kong Y., Yoshida S., Saito Y., et al. CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL. Leukemia 2008, 22:1207-1213.
108. Cox C.V., Diamanti P., Evely R.S., Kearns P.R., Blair A. Expression of CD133 on leukemia-initiating cells in childhood ALL. Blood 2009, 113:3287-3296.
109. Nishida H., Yamazaki H., Yamada T., et al. CD9 correlates with cancer stem cell potentials in human B-acute lymphoblastic leukemia cells. Biochem Biophys Res Commun 2009, 382:57-62.
110. Cox C.V., Martin H.M., Kearns P.R., Virgo P., Evely R.S., Blair A. Characterization of a progenitor cell population in childhood T-cell acute lymphoblastic leukemia. Blood 2007, 109:674-682.
111. Yamazaki H., Nishida H., Iwata S., Dang N.H., Morimoto C. CD90 and CD110 correlate with cancer stem cell potentials in human T-acute lymphoblastic leukemia cells. Biochem Biophys Res Commun 2009, 383:172-177.
112. Armstrong F., de la Grange P.B., Gerby B., et al. NOTCH is a key regulator of human T-cell acute leukemia initiating cell activity. Blood 2009, 113:1730-1740.
113. De Keersmaecker K., Marynen P., Cools J. Genetic insights in the pathogenesis of T-cell acute lymphoblastic leukemia. Haematologica 2005, 90:1116-1127.
114. Radtke F., Wilson A., Mancini S.J., MacDonald H.R. Notch regulation of lymphocyte development and function. Nat Immunol 2004, 5:247-253.
115. Grabher C., von Boehmer H., Look A.T. Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat Rev Cancer 2006, 6:347-359.
116. Weng A.P., Ferrando A.A., Lee W., et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004, 306:269-271.
117. Durig J., Ebeling P., Grabellus F., et al. A novel nonobese diabetic/severe combined immunodeficient xenograft model for chronic lymphocytic leukemia reflects important clinical characteristics of the disease. Cancer Res 2007, 67:8653-8661.
118. Nowakowski. ABCG2 is expressed in a small population of circulating B-cells characterized by expression of self-renewal and early B-cell development genes and resistance to therapy. Blood 2008;112(11):1-1444, 1082.
119. Matsui W., Huff C.A., Wang Q., et al. Characterization of clonogenic multiple myeloma cells. Blood 2004, 103:2332-2336.
120. Rasmussen T., Lodahl M., Hancke S., Johnsen H.E. In multiple myeloma clonotypic CD38-/CD19+/CD27+ memory B cells recirculate through bone marrow, peripheral blood and lymph nodes. Leuk Lymphoma 2004, 45:1413-1417.
121. Matsui W., Wang Q., Barber J.P., et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 2008, 68:190-197.
122. Prince M.E., Sivanandan R., Kaczorowski A., et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 2007, 104:973-978.
123. Zhou L., Wei X., Cheng L., Tian J., Jiang J.J. CD133, one of the markers of cancer stem cells in Hep-2 cell line. Laryngoscope 2007, 117:455-460.
124. van de Wetering M., Sancho E., Verweij C., et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002, 111:241-250.
125. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61:759-767.
126. Knudson A.G. Hereditary cancer, oncogenes, and antioncogenes. Cancer Res 1985, 45:1437-1443.
127. Sell S., Pierce G.B. Maturation arrest of stem cell differentiation is a common pathway for the cellular origin of teratocarcinomas and epithelial cancers. Lab Invest 1994, 70:6-22.
128. Sell S., Leffert H.L. Liver cancer stem cells. J Clin Oncol 2008, 26:2800-2805.
129. Factor V.M., Radaeva S.A., Thorgeirsson S.S. Origin and fate of oval cells in dipin-induced hepatocarcinogenesis in the mouse. Am J Pathol 1994, 145:409-422.
130. Petersen B.E., Goff J.P., Greenberger J.S., Michalopoulos G.K. Hepatic oval cells express the hematopoietic stem cell marker Thy-1 in the rat. Hepatology 1998, 27:433-445.
131. Ma S., Lee T.K., Zheng B.J., Chan K.W., Guan X.Y. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 2008, 27:1749-1758.
132. Yang Z.F., Ngai P., Ho D.W., et al. Identification of local and circulating cancer stem cells in human liver cancer. Hepatology 2008, 47:919-928.
133. Berman D.M., Karhadkar S.S., Maitra A., et al. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 2003, 425:846-851.
134. Lee C.J., Dosch J., Simeone D.M. Pancreatic cancer stem cells. J Clin Oncol 2008, 26:2806-2812.
135. Schmidt C. Lapatinib study supports cancer stem cell hypothesis, encourages industry research. J Natl Cancer Inst 2008, 100:694-695.
136. O'Brien C.S., Howell S.J., Farnie G., Clarke R.B. Resistance to endocrine therapy: are breast cancer stem cells the culprits?. J Mammary Gland Biol Neoplasia 2009, 14:45-54.
137. Ushijima T., Okochi-Takada E. Aberrant methylations in cancer cells: where do they come from?. Cancer Sci 2005, 96:206-211.
138. Watts C.K., Handel M.L., King R.J., Sutherland R.L. Oestrogen receptor gene structure and function in breast cancer. J Steroid Biochem Mol Biol 1992, 41:529-536.
139. Ehtesham M., Mapara K.Y., Stevenson C.B., Thompson R.C. CXCR4 mediates the proliferation of glioblastoma progenitor cells. Cancer Lett 2009, 274:305-312.
140. Read T.A., Fogarty M.P., Markant S.L., et al. Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma. Cancer Cell 2009, 15:135-147.
141. Kurita T., Medina R.T., Mills A.A., Cunha G.R. Role of p63 and basal cells in the prostate. Development 2004, 131:4955-4964.
142. Collins A.T., Berry P.A., Hyde C., Stower M.J., Maitland N.J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005, 65:10946-10951.
143. Maitland N.J., Collins A.T. Prostate cancer stem cells: a new target for therapy. J Clin Oncol 2008, 26:2862-2870.
144. Kasper S. Exploring the origins of the normal prostate and prostate cancer stem cell. Stem Cell Rev 2008, 4:193-201.
145. Gu G., Yuan J., Wills M., Kasper S. Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res 2007, 67:4807-4815.
146. Klarmann G.J., Hurt E.M., Mathews L.A., et al. Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clin Exp Metast 2009, 26:433-446.
147. Patrawala L., Calhoun T., Schneider-Broussard R., et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006, 25:1696-1708.
148. Dubrovska A., Kim S., Salamone R.J., et al. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci USA 2009, 106:268-273.
149. Sharifi N., Hurt E.M., Farrar W.L. Androgen receptor expression in prostate cancer stem cells: is there a conundrum?. Cancer Chemother Pharmacol 2008, 62:921-923.
150. True L., Coleman I., Hawley S., et al. A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci USA 2006, 103:10991-10996.
151. Suvà M.L., Riggi N., Stehle J.C., et al. Identification of cancer stem cells in Ewing's sarcoma. Cancer Res 2009, 69:1776-1781.
152. Takaishi S., Okumura T., Tu S., et al. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 2009, 27:1006-1020.
153. Houghton J., Stoicov C., Nomura S., et al. Gastric cancer originating from bone marrow-derived cells. Science 2004, 306:1568-1571.
154. Kim C.F., Jackson E.L., Woolfenden A.E., et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 2005, 121:823-835.
155. Eramo A., Lotti F., Sette G., et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008, 15:504-514.
156. Tirino V., Camerlingo R., Franco R., et al. The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. Eur J Cardiothorac Surg 2009, 36:446-453.
157. Santin A.D. Prospective identification and characterization of ovarian cancer stem cells: implications for the treatment of chemotherapy resistant/recurrent ovarian disease. Cell Cycle 2009, 8.
158. Baba T., Convery P.A., Matsumura N., et al. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 2009, 28:209-218.
159. Ferrandina G., Bonanno G., Pierelli L., et al. Expression of CD133-1 and CD133-2 in ovarian cancer. Int J Gynecol Cancer 2008, 18:506-514.
160. Kusumbe A.P., Mali A.M., Bapat S.A. CD133-expressing stem cells associated with ovarian metastases establish an endothelial hierarchy and contribute to tumor vasculature. Stem Cells 2009, 27:498-508.
161. Friedman S., Lu M., Schultz A., Thomas D., Lin R.Y. CD133+ anaplastic thyroid cancer cells initiate tumors in immunodeficient mice and are regulated by thyrotropin. PLoS ONE 2009, 4:e5395.
162. Monzani E., Facchetti F., Galmozzi E., et al. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 2007, 43:935-946.
163. Rappa G., Fodstad O., Lorico A. The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells 2008, 26:3008-3017.
164. Dou J., Pan M., Wen P., et al. Isolation and identification of cancer stem-like cells from murine melanoma cell lines. Cell Mol Immunol 2007, 4:467-472.
165. Jaksch M., Munera J., Bajpai R., Terskikh A., Oshima R.G. Cell cycle-dependent variation of a CD133 epitope in human embryonic stem cell, colon cancer, and melanoma cell lines. Cancer Res 2008, 68:7882-7886.
166. Keshet G.I., Goldstein I., Itzhaki O., et al. MDR1 expression identifies human melanoma stem cells. Biochem Biophys Research Commun 2008, 368:930-936.
167. Hendrix M.J., Seftor E.A., Hess A.R., Seftor R.E. Molecular plasticity of human melanoma cells. Oncogene 2003, 22:3070-3075.
168. Selzer E., Wacheck V., Kodym R., et al. Erythropoietin receptor expression in human melanoma cells. Melanoma Res 2000, 10:421-426.
169. Mirmohammadsadegh A., Marini A., Gustrau A., Delia D., et al. Role of erythropoietin receptor expression in malignant melanoma. J Invest Dermatol 2010, 130:201-210.
170. Kumar S.M., Acs G., Fang D., Herlyn M., Elder D.E., Xu X. Functional erythropoietin autocrine loop in melanoma. Am J Pathol 2005, 166:823-830.
171. Kumar S.M., Yu H., Fong D., Acs G., Xu X. Erythropoietin activates the phosphoinositide 3-kinase/Akt pathway in human melanoma cells. Melanoma Res 2006, 16:275-283.
172. Tas F., Oguz H., Argon A., et al. The value of serum levels of IL-6, TNF-alpha, and erythropoietin in metastatic malignant melanoma: serum IL-6 level is a valuable prognostic factor at least as serum LDH in advanced melanoma. Med Oncol 2005, 22:241-246.
173. Nordling C.O. A new theory on cancer-inducing mechanism. Br J Cancer 1953, 7:68-72.
174. Armitage P., Doll R. The age distribution of cancer and a multi-stage theory of carcinogenesis. Br J Cancer 1954, 8:1-12.
175. Knudson A.G. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971, 68:820-823.
176. Cairns J. Mutation selection and the natural history of cancer. Nature 1975, 255:197-200.
177. Gorre M.E., Mohammed M., Ellwood K., et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293:876-880.
178. Shah N.P., Nicoll J.M., Nagar B., et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002, 2:117-125.
179. Turley E.A., Veiseh M., Radisky D.C., Bissell M.J. Mechanisms of disease: epithelial-mesenchymal transition-does cellular plasticity fuel neoplastic progression?. Nat Clin Pract Oncol 2008, 5:280-290.
180. Streubel B., Chott A., Huber D., et al. Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med 2004, 351:250-259.
181. Bhatia R., McGlave P.B., Dewald G.W., Blazar B.R., Verfaillie C.M. Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia: role of malignant stromal macrophages. Blood 1995, 85:3636-3645.
182. Wohrer S., Rabitsch W., Shehata M., et al. Mesenchymal stem cells in patients with chronic myelogenous leukaemia or bi-phenotypic Ph+ acute leukaemia are not related to the leukaemic clone. Anticancer Res 2007, 27:3837-3841.
183. Jootar S., Pornprasertsud N., Petvises S., et al. Bone marrow derived mesenchymal stem cells from chronic myeloid leukemia t(9;22) patients are devoid of Philadelphia chromosome and support cord blood stem cell expansion. Leuk Res 2006, 30:1493-1498.
184. Valent P. Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease. Br J Haematol 2008, 142:361-378.
185. Valent P., Deininger M. Clinical perspectives of concepts on neoplastic stem cells and stem cell-resistance in chronic myeloid leukemia. Leuk Lymphoma 2008, 49:604-609.
186. Clarke M.F. Chronic myelogenous leukemia-identifying the hydra's heads. N Engl J Med 2004, 351:634-636.
187. Frankel A., Liu J.S., Rizzieri D., Hogge D. Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia. Leuk Lymphoma 2008, 49:543-553.
188. Jin L., Lee E.M., Ramshaw H.S., et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 2009, 5:31-42.
189. Roberts A.W., He S., Bradstock K.F., et al. A phase 1 and correlative biological study of CSL360(anti-CD123 mAb) in AML. Blood 2008, 112:1015-1016.
190. Sharma S.V., Bell D.W., Settleman J., Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007, 7:169-181.
191. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr 2001, 131:3109S-3120S.
192. Wakefield L.M., Roberts A.B. TGF-beta signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev 2002, 12:22-29.
193. Korc M., Friesel R.E. The role of fibroblast growth factors in tumor growth. Curr Cancer Drug Targets 2009, 9:639-651.
194. Xu Q., Simpson S.E., Scialla T.J., Bagg A., Carroll M. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 2003, 102:972-980.
195. Recher C., Dos Santos C., Demur C., Payrastre B. mTOR, a new therapeutic target in acute myeloid leukemia. Cell Cycle (Georgetown, Tex) 2005, 4:1540-1549.
196. Böhm A., Aichberger K.J., Mayerhofer M., et al. Targeting of mTOR is associated with decreased growth and decreased VEGF expression in acute myeloid leukaemia cells. Eur J Clin Invest 2009, 39:395-405.
197. Weisberg E., Banerji L., Wright R.D., et al. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. Blood 2008, 111:3723-3734.
198. Ratain M.J., Eisen T., Stadler W.M., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006, 24:2505-2512.
199. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
200. Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006, 24:16-24.
201. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
202. Cheng A.L., Kang Y.K., Chen Z., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10:25-34.
203. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351:337-345.
204. Rosell R., Robinet G., Szczesna A., et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol 2008, 19:362-369.
205. Mohi M.G., Boulton C., Gu T.L., et al. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci USA 2004, 101:3130-3135.
206. Noh W.C., Mondesire W.H., Peng J., et al. Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 2004, 10:1013-1023.
207. Chan S. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 2004, 91:1420-1424.
208. Hartog H., Wesseling J. Boezen HM, van der Graaf WT, The insulin-like growth factor 1 receptor in cancer: old focus, new future. Eur J Cancer 2007, 43:1895-1904.
209. Weroha S.J., Haluska P. IGF-1 receptor inhibitors in clinical trials-early lessons. J Mammary Gland Biol Neoplasia 2008, 13:471-483.
210. Flandrin P., Guyotat D., Duval A., et al. Significance of heat-shock protein (HSP) 90 expression in acute myeloid leukemia cells. Cell Stress Chaperones 2008, 13:357-364.
211. Thomas X., Campos L., Mounier C., et al. Expression of heat-shock proteins is associated with major adverse prognostic factors in acute myeloid leukemia. Leukemia Res 2005, 29:1049-1058.
212. Thomas X., Campos L., Le Q.H., Guyotat D. Heat shock proteins and acute leukemias. Hematology (Amsterdam, Netherlands) 2005, 10:225-235.
213. Mayerhofer M., Gleixner K.V., Mayerhofer J., et al. Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib. Blood 2008, 111:2200-2210.
214. Gleixner K.V., Mayerhofer M., Vales A., et al. Targeting of Hsp32 in solid tumors and leukemias: a novel approach to optimize anticancer therapy. Curr Cancer Drug Targets 2009, 9:675-689.
215. Al-Hajj M., Clarke M.F. Self-renewal and solid tumor stem cells. Oncogene 2004, 23:7274-7282.
216. Graziano A., d'Aquino R., Tirino V., Desiderio V., Rossi A., Pirozzi G. The stem cell hypothesis in head and neck cancer. J Cell Biochem 2008, 103:408-412.
217. Chaudry M.A., Sales K., Ruf P., Lindhofer H., Winslet M.C. EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges. Br J Cancer 2007, 96:1013-1019.
218. Rege T.A., Hagood J.S. Thy-1 as a regulator of cell-cell and cell-matrix interactions in axon regeneration, apoptosis, adhesion, migration, cancer, and fibrosis. FASEB J 2006, 20:1045-1054.
219. Moretti S., Lanza F., Dabusti M., et al. CD123 (interleukin 3 receptor alpha chain). J Biol Regul Homeost Agents 2001, 15:98-100.
220. Tarrant J.M., Robb L., van Spriel A.B., Wright M.D. Tetraspanins: molecular organisers of the leukocyte surface. Trends Immunol 2003, 24:610-617.
221. Pescovitz M.D. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant 2006, 6:859-866.
222. Donnenberg V.S., Donnenberg A.D. Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol 2005, 45:872-877.
223. Frank N.Y., Pendse S.S., Lapchak P.H., et al. Regulation of progenitor cell fusion by ABCB5 P-glycoprotein, a novel human ATP-binding cassette transporter. J Biol Chem 2003, 278:47156-47165.
224. Frank N.Y., Margaryan A., Huang Y., et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 2005, 65:4320-4333.
225. Bakker A.B., van den Oudenrijn S., Bakker A.Q., et al. C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia. Cancer Res 2004, 64:8443-8450.
226. Maiese K., Li F., Chong Z.Z. New avenues of exploration for erythropoietin. JAMA 2005, 293:90-95.